CytoSorbents Corp logo

CytoSorbents Corp

$ 1.51 +0.11 (+7.86%) 10:08 PM EST
P/E:
At Loss
P/B:
1.40
Market Cap:
$ 65.80M
Enterprise V:
$ 44.35M
Volume:
119.26K
Avg Vol (2M):
163.50K
Also Trade In:
Volume:
119.26K
Market Cap $:
65.80M
PE Ratio:
At Loss
Avg Vol (2-Month):
163.50K
Enterprise Value $:
44.35M
PB Ratio:
1.40
GF Score:
Year:
To
10Y: -%
Above Low: +NaN%
Below High: NaN%
Alerts Website SEC Filings Stock Report
Dataset
Financial Download

Business Description

Description
CytoSorbents Corp is a critical care immunotherapy leader commercializing its European Union approved CytoSorb blood purification technology to treat deadly inflammation in critically ill and cardiac surgery patients in around 55 countries. The company is conducting its pivotal REFRESH 2 - AKI cardiac surgery trial, designed to support U.S. FDA approval. The company's product portfolio consists of CytoSorb, ContrastSorb, VetResQ, HemoDefend and others. The company has around 19 issued U.S. patents, multiple patents issued internationally, and a broad patent application portfolio pending. Geographically it derives substantial revenue from product sales in Germany.
Name Current Vs Industry Vs History
Cash-To-Debt 2.23
Equity-to-Asset 0.67
Debt-to-Equity 0.28
Debt-to-EBITDA -0.46
Interest Coverage N/A
N/A
N/A
Piotroski F-Score 2/9
0
1
2
3
4
5
6
7
8
9
Altman Z-Score -3.87
Distress
Grey
Safe
Beneish M-Score -2.66
Manipulator
Not Manipulator
WACC vs ROIC
WACC
ROIC
Name Current Vs Industry Vs History
5-Day RSI 56.75
9-Day RSI 46.81
14-Day RSI 43.83
6-1 Month Momentum % -41.27
12-1 Month Momentum % -77.1

Liquidity Ratio

Name Current Vs Industry Vs History
Current Ratio 3.95
Quick Ratio 3.47
Cash Ratio 2.86
Days Inventory 149.7
Days Sales Outstanding 54.48
Days Payable 104.42

Dividend & Buy Back

Name Current Vs Industry Vs History
3-Year Average Share Buyback Ratio -11

Financials (Next Earnings Date:2022-11-04 Est.)

CTSO's 30-Y Financials

Guru Trades

See Details
To

Insider Trades

See Details
To

Gurus Latest Trades with NAS:CTSO

Peter Lynch Chart

Y-axis scale:
Interactive Chart
To

Performance

Dividend
To

Annualized Return %

Symbol 1 Week 1 Month 3 Months 6 Months YTD 1 Year 3 Years 5 Years 10 Years

Total Annual Return %

Symbol 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013

Executives

Valuation Box

Year:

Analyst Estimate

Key Statistics

Name Value
Revenue (TTM) (Mil $) 33.855
EPS (TTM) ($) -0.82
Beta 0
Volatility % 49.6
14-Day RSI 43.83
14-Day ATR ($) 0.151036
20-Day SMA ($) 1.6245
12-1 Month Momentum % -77.1
52-Week Range ($) 1.18 - 8.095
Shares Outstanding (Mil) 43.58

Piotroski F-Score Details

Year:
Component Result
Piotroski F-Score 2
Positive ROA
Positive CFROA
Higher ROA yoy
CFROA > ROA
Lower Leverage yoy
Higher Current Ratio yoy
Less Shares Outstanding yoy
Higher Gross Margin yoy
Higher Asset Turnover yoy

CytoSorbents Corp Filings

Document Form Filing Date
No Filing Data

CytoSorbents Corp Analysis

Share your research

Headlines

See More
No news.